Literature DB >> 2040070

An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis.

J Folts1.   

Abstract

Coronary artery bypass grafts, angioplasty, and thrombolysis are beneficial procedures for patients with coronary artery disease. However, these procedures can fail by mechanisms related to interactions between platelets and the damaged arterial wall. An experimental model for studying some of the mechanisms of platelet interaction with endothelial- and medial-damaged stenosed arteries is described. Dogs or pigs are anesthetized, and the chest opened. The heart is exposed, the circumflex or left anterior descending coronary artery is dissected out, and an EMF or Doppler flow probe is placed on it. Distal to the flow probe, the artery is clamped with a vascular clamp to produce endothelial and/or medial injury. Then, an encircling plastic cylinder is placed around the outside of the injured artery, producing a "critical stenosis." Acute platelet thrombus formation begins to occur in the stenosed lumen, gradually increasing the amount of stenosis. This causes the coronary flow to decline and reach zero flow when the artery is completely occluded. Then, the thrombus is embolized into the distal circulation, and flow is restored to normal levels. This occurs repeatedly causing cyclic flow reductions (CFRs). These CFRs can be made larger and to occur more frequently by increasing in vivo platelet activity, by raising the plasma catecholamine levels, or by increasing the collagen exposed in the stenosed lumen by increased medial damage. If an effective dose of an antiplatelet agent is given, the CFRs will be decreased in size and frequency or abolished entirely. Aspirin and other agents abolish the CFRs in this model; however, CFRs can be renewed by infusions of catecholamines or platelet activating factor. Thus, the model may be useful for studying mechanisms that enhance or inhibit arterial thrombosis in stenosed arteries with endothelial and medial injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040070

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Targeted Coronary Thrombolysis via "Pericardial" Administration of Lytic Agents?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-09       Impact factor: 2.300

2.  High shear stress marks: the vulnerable target with von Willebrand factor for platelet deployment -letter-.

Authors:  H Gilutz
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

3.  Discordant cardiac biomarker levels independently predict outcome in ST-segment elevation myocardial infarction.

Authors:  Gregor Leibundgut; Michael Gick; Olivier Morel; Miroslaw Ferenc; Klaus-Dieter Werner; Thomas Comberg; Rolf-Peter Kienzle; Heinz Joachim Buettner; Franz-Josef Neumann
Journal:  Clin Res Cardiol       Date:  2015-11-12       Impact factor: 5.460

4.  Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling.

Authors:  Kumar B Reddy; Dawn M Smith; Edward F Plow
Journal:  J Cell Sci       Date:  2008-04-22       Impact factor: 5.285

5.  Standardizing a simpler, more sensitive and accurate tail bleeding assay in mice.

Authors:  Yang Liu; Nicole L Jennings; Anthony M Dart; Xiao-Jun Du
Journal:  World J Exp Med       Date:  2012-04-20

Review 6.  Nitric oxide insufficiency and atherothrombosis.

Authors:  Barbara Voetsch; Richard C Jin; Joseph Loscalzo
Journal:  Histochem Cell Biol       Date:  2004-08-26       Impact factor: 4.304

Review 7.  Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.

Authors:  Ian C Gilchrist
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.

Authors:  Thomas Gremmel; Ivan B Yanachkov; Milka I Yanachkova; George E Wright; Joseph Wider; Vishnu V R Undyala; Alan D Michelson; Andrew L Frelinger; Karin Przyklenk
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-01-07       Impact factor: 8.311

9.  Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.

Authors:  K Przyklenk; A L Frelinger; M D Linden; P Whittaker; Y Li; M R Barnard; J Adams; M Morgan; H Al-Shamma; A D Michelson
Journal:  J Thromb Haemost       Date:  2009-11-17       Impact factor: 5.824

10.  Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.

Authors:  Matthew D Linden; Marc R Barnard; A L Frelinger; Alan D Michelson; Karin Przyklenk
Journal:  Thromb Res       Date:  2007-08-28       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.